title: Treatment of central nervous system lymphoma in rats with intraventricular rituximab and serum.
abstract: B cell lymphomas often develop in the central nervous system (CNS). Although rituximab (RTX) has been widely used for most B cell lymphomas, the efficacy for CNS lymphomas has yet to be elucidated. A major concern is that RTX might not reach lymphoma lesions, and either the antibody-dependent cellular cytotoxicity or complement-dependent cytotoxicity might not substantially operate in the CNS environment. Here we investigated the potential usefulness of co-administering RTX and human serum intraventricularly in nude rats carrying human B cell lymphomas in the CNS. Raji, a CD20-positive lymphoma cell line, was inoculated into the cerebrum of F344 (rnu/rnu) nude rats. After several days, RTX and human serum were delivered into the ipsilateral lateral ventricle via a cannula. Intraventricularly administered RTX was localized specifically at the lymphoma lesions, indicating that RTX penetrated the ependymal layer of the lateral ventricle to reach the tumor lesion, where it specifically bound to the lymphoma cells. The combination of RTX and serum (n = 12), but not RTX alone (n = 13), significantly extended the survival of the rats (P = 0.049). Intraventricular administration of RTX and serum in a rat/human CNS lymphoma model might be a potential novel treatment for CNS lymphomas of B cell origin. Clinical trials are warranted.
authors.affiliation: Clinical and Experimental Hematology, Major of Clinical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, 305-8575, Japan.
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Miyake
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Okoshi
authors.forename: Takayuki
authors.initials: T
authors.lastname: Machino
authors.forename: Shigeru
authors.initials: S
authors.lastname: Chiba
mesh_terms: D000818:Animals; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage* / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D016543:Central Nervous System Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000473:pathology; D051381:Rats; D011923:Rats, Nude; D000069283:Rituximab; D044967:Serum / Q000378:metabolism*
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab
references.citation: Blood. 2002 Feb 1;99(3):1038-43
references.pmid: 11807010
references.citation: Blood. 2000 Jun 15;95(12):3900-8
references.pmid: 10845926
references.citation: Jpn J Clin Oncol. 2008 May;38(5):373-80
references.pmid: 18413337
references.citation: J Clin Oncol. 2007 Apr 10;25(11):1350-6
references.pmid: 17312328
references.citation: EMBO J. 1988 Mar;7(3):711-7
references.pmid: 2456210
references.citation: J Exp Med. 1988 Jun 1;167(6):1975-80
references.pmid: 3260267
references.citation: Leukemia. 1998 Dec;12(12):2029-33
references.pmid: 9844934
references.citation: Glia. 1998 Apr;22(4):348-59
references.pmid: 9517567
references.citation: Int J Hematol. 2009 Jun;89(5):577-83
references.pmid: 19353238
references.citation: Cancer Sci. 2007 Sep;98(9):1368-72
references.pmid: 17640305
references.citation: J Immunol. 2003 Aug 1;171(3):1581-7
references.pmid: 12874252
references.citation: Adv Drug Deliv Rev. 1999 Apr 5;36(2-3):211-227
references.pmid: 10837717
references.citation: Pharm Res. 2005 Jul;22(7):1011-37
references.pmid: 16028003
references.citation: J Cereb Blood Flow Metab. 1997 Jul;17(7):713-31
references.pmid: 9270488
references.citation: Clin Cancer Res. 2003 Dec 15;9(17):6567-71
references.pmid: 14695162
references.citation: Clin Cancer Res. 2009 Mar 15;15(6):1989-97
references.pmid: 19276270
references.citation: Mol Genet Metab. 2005 Sep-Oct;86(1-2):141-9
references.pmid: 16006167
references.citation: Clin Cancer Res. 2006 Jul 1;12(13):4027-35
references.pmid: 16818702
references.citation: Haematologica. 2004 Jun;89(6):753-4
references.pmid: 15194546
references.citation: Blood. 2002 Feb 15;99(4):1314-9
references.pmid: 11830481
references.citation: J Neurooncol. 2006 Jan;76(2):131-8
references.pmid: 16284923
references.citation: Invest Ophthalmol Vis Sci. 2008 Nov;49(11):4738-45
references.pmid: 18552383
references.citation: Cancer Sci. 2006 Jan;97(1):80-3
references.pmid: 16367925
references.citation: Blood. 1994 Jan 15;83(2):435-45
references.pmid: 7506951
references.citation: Cell Immunol. 2000 Aug 25;204(1):55-63
references.pmid: 11006018
references.citation: J Immunol. 2001 Feb 15;166(4):2717-26
references.pmid: 11160337
references.citation: Cancer Immunol Immunother. 2002 Mar;51(1):15-24
references.pmid: 11845256
references.citation: Glia. 1998 Jan;22(1):72-85
references.pmid: 9436789
references.citation: Expert Rev Neurother. 2009 Oct;9(10):1497-509
references.pmid: 19831839
references.citation: Blood. 2003 Jan 15;101(2):466-8
references.pmid: 12393404
references.citation: Blood. 2004 Sep 15;104(6):1793-800
references.pmid: 15172969
references.citation: J Neurooncol. 1999 Jun;43(2):153-60
references.pmid: 10533727
references.citation: Leuk Lymphoma. 2001 Aug;42(4):731-8
references.pmid: 11697503
references.citation: Blood. 2003 Feb 1;101(3):949-54
references.pmid: 12393572